Kitazato America, Inc.

Kitazato America, Inc. is a US subsidiary of Kitazato, a Japanese biotechnology corporation specializing in research, development, and manufacturing of medical devices for assisted reproductive technology (ART) and in vitro fertilization (IVF). The company provides a comprehensive portfolio of over 550 product references covering the complete IVF cycle, including oocyte retrieval needles, micro-tools, culture media, oils, embryo transfer catheters, and the proprietary Cryotop® vitrification method—recognized as the system that popularized vitrification technology in reproductive medicine. Core product lines include Cryotop® vitrification devices and systems, Hypure® oils (heavy and light formulations) for embryo culture, ICSI injection pipettes and micro-tools, oocyte retrieval needles, embryo transfer (ET) and intrauterine insemination (IUI) catheters (including the RYDEN® and EC-PRO® lines), and specialized IVF and andrology culture media. The company has developed an Ultra-Fast Vitrification Protocol (CE marked) designed to simplify oocyte vitrification and optimize oocyte viability protection. Kitazato serves fertility clinics, ART laboratories, and reproductive medicine practices globally, with significant clinical adoption evidenced by extensive published scientific literature and thousands of clinic references. The company maintains regulatory compliance with CE marking and serves as a trusted partner for clinicians seeking evidence-based vitrification and embryo culture solutions.